Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
SRTS Transcript
Sensus Healthcare, Inc. (SRTS) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call reveals mixed signals. While the company faces financial strain with a negative EBITDA and net loss, it shows potential for growth with expanding international sales and recurring revenue streams. The absence of sales to the largest customer is a setback, but there's optimism for future returns. The Q&A highlights interest in new CPT codes, indicating potential for future revenue growth. However, the lack of clear timelines for revenue inflection and the ongoing financial strain balance out the positives, resulting in a neutral sentiment for the stock price movement.
Sensus Healthcare, Inc. (SRTS) Q4 2025 Earnings Call Transcript
Unknown2-12
The company reported disappointing financial results with significant revenue and profit declines, resulting in a net loss. Despite optimistic guidance and international expansion plans, uncertainties like the largest customer's exclusion from projections, unclear FDA approval timelines, and vague management responses during the Q&A raise concerns. Increased expenses and negative EBITDA further contribute to a negative sentiment. Although there is potential in international markets and reimbursement changes, the overall outlook remains negative due to financial underperformance and uncertainties.
Sensus Healthcare, Inc. (SRTS) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call reveals declining financial metrics, including reduced units sold, gross profit, and increased net loss, indicating weakening financial health. Despite some positive elements, like international expansion and potential breakeven in Q4, the negative trends, including a significant drop in gross margin and increased operating expenses, dominate. The Q&A section did not alleviate concerns, as management's responses lacked clarity on critical timelines. Given these factors, the stock is likely to experience a negative reaction in the near term.
Sensus Healthcare, Inc. (SRTS) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call revealed significant declines in gross profit, gross margin, and a shift from net income to net loss, indicating financial challenges. The Q&A highlighted uncertainties around CMS reimbursement, impacting sales and causing a large customer to pause purchases. Despite some international sales optimism, the lack of clear guidance on reimbursement and increased operating expenses suggest a negative short-term outlook. The overall sentiment leans negative due to financial performance issues and unresolved reimbursement concerns.
SRTS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
